Selected article for: "protease inhibitor and RNA dependent RNA polymerase"
Author: Wang, Sheng-Fan; Chen, Kuan-Hsuan; Wang, Szu-Yu; Yarmishyn, Aliaksandr A.; Lai, Wei-Yi; Lin, Yi-Ying; Wang, Mong-Lien; Chou, Shih-Jie; Yang, Yi-Ping; Chang, Yuh-Lih
Title: The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2
  • Cord-id: 7ln7p715
  • Document date: 2020_5_20
    • ID: 7ln7p715
    Snippet: Recently, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was quickly identified as the causal pathogen leading to the outbreak of SARS-like illness all over the world. As the SARS-CoV-2 infection pandemic proceeds, many efforts are being dedicated to the development of diverse treatment strategies. Increasing evidence showed potential therapeutic agents directly acting against SARS-CoV-2 virus, such as interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, vi
    Document: Recently, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was quickly identified as the causal pathogen leading to the outbreak of SARS-like illness all over the world. As the SARS-CoV-2 infection pandemic proceeds, many efforts are being dedicated to the development of diverse treatment strategies. Increasing evidence showed potential therapeutic agents directly acting against SARS-CoV-2 virus, such as interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells, and nucleocytoplasmic trafficking inhibitor. To date, several direct anti-SARS-CoV-2 agents have demonstrated promising in vitro and clinical efficacy. This article reviews the current and future development of direct acting agents against SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and additional ifn: 1
    • acid base vaccine and acute respiratory syndrome: 1
    • activate immune system and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activate immune system and adaptive immune response: 1
    • acute respiratory syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive immune response innate immunity: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and adaptor protein: 1, 2, 3, 4, 5
    • acute respiratory syndrome and adenosine structural similarity: 1
    • acute respiratory syndrome and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immune response and lopinavir ritonavir: 1
    • adaptive immune response innate immunity and additional ifn: 1